Pharmaceutical treatment for different types of epilepsy generally still relies on tried-and-true generics, despite recent efforts by drug manufacturers to introduce new branded medications into the mix, PBM insiders say. Xcopri (cenobamate tablets) launched in May for the treatment of partial-onset seizures in adults. According to manufacturer SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., clinical trials have shown “significant reductions in seizure frequency compared to placebo at all doses studied, and as many as one in five patients achieved zero seizures during the maintenance phase.”
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.